TY - JOUR
T1 - Evidence-Based Rehabilitation for Multiple Sclerosis Made Easy
AU - Heine, Martin
AU - Beckerman, Heleen
AU - Hämäläinen, Päivi
AU - de Groot, Vincent
N1 - Funding Information:
Golchehreh Ahmadi Janella Clarke Rachel Galioto ioral therapy Dpoaspithivneely Kaoffsects fatigue in Kpaamtieilnat sR wasitohv amultiple scle-Acknowledgments: Kevin N. Alschuler The authors acknowledge the multidisciStanley Cohan Eduard Gappmaier-rosis: results of a randomized controlled trial. Laleh Lajevardi Linda (Miller) RenfrewMult Scler. 2017;23: plinary advisory board Lilyana Amezcua that provided invaluable input throughout theBruce A. Cohen Hina Garg 1542-1553. Megan Langille Mary Rensel course of APPECO development.Saeideh Aminian Jeffrey Cohen Setareh Ghahari11. Blikman LJ, van Meeteren J, Twisk JW, et al. Effectiveness of energyYvonne C. Learmonth Cristina Roman conservation management on fatigue and participation in multiple scle-Georgia Andreopoulou Nananda F. Col Myla Goldman Christine Leithead Scott Rooney Financial Disclosures:The authors declare no conflicts of interest. rosis: a randomized controlled trial. Mult Scler. 2017;23:1527-1541. Rebekah H. Anguiano William L. Conte Susan Gould Fogerite12. Pöttgen J, MosSusan Linders-Morris R, Wendebourg J-Brian M. SandroffM, et al. Randomised con- Alexander S. Aruin Devon Conway Lisa B. Grech trolled trial of aH seeildf-gi uMidaeldo noinline fatigue inJtoerrdveannt ioSnch inu lmtzultiple sclero-Funding/Support:Deborah Backus The development of APPECO has been finanJoanna Cooper Elizabeth- S. Gromsisi.s cJ hNeurol NMeuarorksu Mrg .P Msycahñiaagtroy. 2018;8M9:e9g7a0n-9 S7e6a.y cially supported by Sanofi Genzyme (phase 1; through RIMS). TheJacci Bainbridge Patricia Coyle Chamika Hawkins-Taylor13. Thomas S, Thomas PW, Kersten P, et al. A pragmatic parallel armJames J. Marriott Angela Senders Dutch MS Research Foundation (PP 18-001) and Roche financiallyBarbara Baker William J. Culpepper Christoph Heesenmulti-centre randomised controlled trial to assess the effectiveness andLori Mayer Amy Lee Sesel cost-effectiveness of a group-based fatigue management programme supApolirztae dB ethne- Zmaachinatreinaance of tGhee rpalladtifnoer mD aapnudl data extractioLni loyf JMunSg Henson Luanne Metz Christopher Sexton (FACETS) for people with multiple sclerosis. J Neurol Neurosurg Psy- rehaSbhielliltay tBioenn sjatumdiinesy related to Adlei pDreeshsgiohna,n piain, and mobilityP.hu D. Hoangchiatry.2013;84:1092-1099.Deborah M. Miller Dinesh Sivakolundu Robert Bermel Kate Delaney Gabriel Hoffnung14. Grossman P, Kappos L, Gensicke H, et al. MS quality of life, depresMichal Minar Matthew Sorenson - ReferencesSandipan Bhattacharjee Samantha Domingo Le Hahn Hua sion, and fatigSuaera ihm Apr.o Mveo rarfotewr mindfulneJassc otbra Jin. iSnogs: nao frfandomized 1. Valerie J. BlockAmatya B, Khan F, Galea M. Rehabilitation for people with multipleAndrew Edwards Dejan Jakimovskitrial. Neurology.Brandon Moss2010;75:1141-1149. Amy Sullivan Theodore R. Brownsclerosis: an overview of Cochrane Reviews. Keith R. EdwardsCochrane Database SystMikael B. Jensen-Johansen15. Mäntynen A, Rosti-Otajärvi E, Koivisto K, et al. NeuropsychologicalRaoof Negaresh Matthew Sutliff Therese BurkeRev. 2019;1:CD012732. Jenny Feng Nevin A. John rehabilitation dYlva Elisabet Nilsagårdoes not improve cognitive perfJenifer J. Thomasormance but reduces 2. Garner P, Hopewell S, Chandler J, et al. When and how to update perceived cognitive deficits in patients with multiple sclerosis: a ran-Margaret Cadden Peter Feys Joshua Johnson Ahmed Obeidat Moira Tzitzika systematic reviews: consensus and checklist. BMJ. 2016;354:i3507. domised, controlled, multi-centre trial. Mult Scler. 2014;20:99-107. 3.Katie L.J. CederbergSteultjens EE, Dekker JJ, Bouter LM, et al. Occupational therapy forMarcia Finlayson Turhan Kahraman16. Campbell J, Langdon D, Cercignani M, et al. A randomised controlledGabriel Pardo Andrea T. White Mmuirletilpal eC secrglehroetsis [publishedC oencliilniee Fajheeldasdta dof print July 21H, 2er0b0e3rt]. Karpatkitrnial of efficacyF oraf nccoigsncoiti vPee rreezhabilitation iJne fmf uWltipillke esnclerosis: a cogni-LCeoigchhr Canhea Drvaettabase Syst Rev.C doorie:1y0 C.1. 0F0o2r/d14651858.CD00W36il0li8am. A. Kilgotive, behaviourLaal,r aa nPdi lMutRtIi study. Neural PlCasetc.i2li0a1 W6;i2n0b1e6rg:4292585. 4. Heine M, van de Port I, Rietberg MB, van Wegen EEH, Kwakkel G. 17. Carr SE, das Nair R, Schwartz AF, et al. Group memory rehabilitation Exercise therapy for fatigue in multiple sclerosis. Cochrane Database for people with multiple sclerosis: a feasibility randomized controlled Syst Rev. 2015;9:CD009956. trial. Clin Rehabil. 2014;28:552-561. 5. Sadeghi-Bazargani H, Tabrizi JS, Azami-Aghdash S. Barriers to 18. Chiaravalloti ND, Moore NB, Nikelshpur OM, et al. An RCT to treat evidence-based medicine: a systematic review. J Eval Clin Pract. learning impairment in multiple sclerosis: The MEMREHAB trial. Neurol- 2014;20:793-802. ogy. 2013;81:2066-2072. 6. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interven-19. Bombardier CH, Ehde DM, Gibbons LE, et al. Telephone-based physi-tions: Template for Intervention Description and Replication (TIDieR) cal activity counseling for major depression in people with multiple checklist and guide. BMJ. 2014;348:g1687. sclerosis. J Consult Clin Psychol. 2013;81:89-99. 7. O’Neill J, Tabish H, Welch V, et al. Applying an equity lens to inter-20. Kayes NM, Martin RA, Bright FA, Kersten P, Pollock A . Optimising the ventions: using PROGRESS ensures consideration of socially stratifying real-world impact of rehabilitation reviews: increasing the relevance factors to illuminate inequities in health. J Clin Epidemiol. 2014;67: and usability of systematic reviews in rehabilitation. Eur J Phys Rehabil 56-64. Med. 2019;55:331-341.
Funding Information:
The development of APPECO has been financially supported by Sanofi Genzyme (phase 1; through RIMS). The Dutch MS Research Foundation (PP 18-001) and Roche financially supported the maintenance of the platform and data extraction of MS rehabilitation studies related to depression, pain, and mobility.
Publisher Copyright:
© 2020 Consortium of Multiple Sclerosis Centers.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - With the current rate in growth of evidence in multiple sclerosis (MS) rehabilitation, systematic reviews and clinical guidelines typically lag behind the most currently published research findings. In addition, most health care professionals lack the time, resources, or adequate skills to identify and evaluate new evidence, and hands-on tools to implement the latest evidence into clinical practice are often lacking or not readily available. The Applying Evidence with Confidence (APPECO) platform is a newly developed online tool that addresses these key challenges. APPECO was initiated as a proof-of-concept for the common MS symptoms fatigue and cognitive function. Subsequently, intervention studies about depression, pain, and mobility were added. APPECO currently hosts detailed information from 250 randomized clinical trials, 293 interventions, and 1250 effect sizes on 53 patient outcomes. Few studies with high quality (ie, low risk of bias) are available specifically designed to test the benefits of MS rehabilitation on fatigue (n = 5 [2.4%]), cognitive function (n = 4 [1.6%]), and depression (n = 2 [0.8%]). No high-quality studies were included for pain and mobility. APPECO has the potential to address key challenges in evidence-based rehabilitation medicine for MS and to facilitate swift knowledge translation from evidence into clinical practice. Sustainability of APPECO depends on a continuous resource impulse (eg, financial, time, editorial management, platform maintenance) to ensure up-to-date information across all relevant MS symptoms and activity limitations (≈2-6 randomized controlled trials per month). Ways to optimize knowledge translation in the absence of high-quality evidence in APPECO need to be explored further. Int J MS Care. 2020;22:263-269.
AB - With the current rate in growth of evidence in multiple sclerosis (MS) rehabilitation, systematic reviews and clinical guidelines typically lag behind the most currently published research findings. In addition, most health care professionals lack the time, resources, or adequate skills to identify and evaluate new evidence, and hands-on tools to implement the latest evidence into clinical practice are often lacking or not readily available. The Applying Evidence with Confidence (APPECO) platform is a newly developed online tool that addresses these key challenges. APPECO was initiated as a proof-of-concept for the common MS symptoms fatigue and cognitive function. Subsequently, intervention studies about depression, pain, and mobility were added. APPECO currently hosts detailed information from 250 randomized clinical trials, 293 interventions, and 1250 effect sizes on 53 patient outcomes. Few studies with high quality (ie, low risk of bias) are available specifically designed to test the benefits of MS rehabilitation on fatigue (n = 5 [2.4%]), cognitive function (n = 4 [1.6%]), and depression (n = 2 [0.8%]). No high-quality studies were included for pain and mobility. APPECO has the potential to address key challenges in evidence-based rehabilitation medicine for MS and to facilitate swift knowledge translation from evidence into clinical practice. Sustainability of APPECO depends on a continuous resource impulse (eg, financial, time, editorial management, platform maintenance) to ensure up-to-date information across all relevant MS symptoms and activity limitations (≈2-6 randomized controlled trials per month). Ways to optimize knowledge translation in the absence of high-quality evidence in APPECO need to be explored further. Int J MS Care. 2020;22:263-269.
UR - http://www.scopus.com/inward/record.url?scp=85126677316&partnerID=8YFLogxK
U2 - 10.7224/1537-2073.2019-100
DO - 10.7224/1537-2073.2019-100
M3 - Article
AN - SCOPUS:85126677316
SN - 1537-2073
VL - 22
SP - 263
EP - 269
JO - International Journal of MS Care
JF - International Journal of MS Care
IS - 6
ER -